The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells
Open accessAbstract
The aim of this study was to assess paclitaxel resistant-epithelial ovarian carcinoma (EOC) cells for cellular morphology, motility, and molecular changes consistent with epithelial-mesenchymal transition (EMT). The human EOC cell lines NOS-2, TAOV and SKOV-3 were continuously exposed to increasing doses of paclitaxel to establish three stable cell lines resistant to paclitaxel (NOS-PR, TAOV-PR, and SKOV-PR cells, respectively). Using these cell lines, cellular functions such as motility, invasive ability, and proliferative potential were assessed. Several molecules involved in EMT or cell invasiveness were assessed using Western blot analysis. In a peritoneal metastasis model using mice inoculated with NOS-2 or NOS-PR cells, we investigated the differences of peritoneal dissemination and survival time. NOS2-PR cells showed phenotypic changes consistent with EMT; with spindle-shaped morphology and enhanced pseudopodia formation. Western blot analysis revealed decreased expression of the epithelial adhesion molecule, E-cadherin and an increase in mesenchymal markers such as vimentin, fibronectin and smooth-muscle actin in NOS-PR cells compared to NOS-2 cells. The NOS2-PR cells displayed increased expression of Snail and Twist, EMT-regulatory transcription factors. Migratory potential in a wound assay and metastatic potential to the peritoneum of mice were markedly enhanced in NOS2-PR cells compared to NOS-2 cells. These data suggest that there is a possible link between chronic paclitaxel-resistance and induction of the EMT in EOC cells. It is possible that therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
The Two-Handed E Box Binding Zinc Finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., & van Roy, F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00260-x · Cited by 1,394
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Leaving the neighborhood: molecular mechanisms involved during epithelial‐mesenchymal transition
Savagner, P. (2001) · BioEssays · doi:10.1002/bies.1132 · Cited by 679
Yang, A. D., Fan, F., Camp, E. R., van Buren, G., Liu, W., Somcio, R., Gray, M. J., Cheng, H., Hoff, P. M., & Ellis, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0038 · Cited by 526
Induction and regulation of epithelial–mesenchymal transitions
Boyer, B., Vallés, A. M., & Edme, N. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00427-5 · Cited by 436
Taxol (paclitaxel): mechanisms of action.
Horwitz, S. B. (1994) · PubMed · Cited by 434
Yang, A. D., Camp, E. R., Fan, F., Shen, L., Gray, M. J., Liu, W., Somcio, R., Bauer, T. W., Wu, Y., Hicklin, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3086 · Cited by 281
Lee, J. T., Steelman, L. S., & McCubrey, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1612 · Cited by 156
Tumor Metastasis: A New Twist on Epithelial–Mesenchymal Transitions
Vernon, A. E., & LaBonne, C. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.048 · Cited by 156
Daraï, É., Scoazec, J., Walker, F., Mlika-Cabanne, N., Feldmann, G., Madélénat, P., & Potet, F. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90007-1 · Cited by 146
Kajiyama, H., Kikkawa, F., Suzuki, T., Shibata, K., Ino, K., & Mizutani, S. (2002) · PubMed · Cited by 115
Self-citationElliott, B. E., Hung, W., Boag, A. H., & Tuck, A. B. (2002) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y02-010 · Cited by 93
Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas
Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., & Lopes, C. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh387 · Cited by 68
E-Cadherin Complex Protein Expression and Survival in Ovarian Carcinoma
Davidson, B., Gotlieb, W. H., Ben‐Baruch, G., Nesland, J. M., Bryne, M., Goldberg, I., Kopolovic, J., & Berner, A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5964 · Cited by 40
Cited by
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells
Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 870
Epithelial-mesenchymal transition in cancer development and its clinical significance
Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., & Mori, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01419.x · Cited by 780
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Metadata
- Authors
- Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M., Ino, K., Nawa, A., & Kikkawa, F.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2007-08-01
- Volume
- 31
- Issue
- 2
- Pages
- 277-83
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2091729045
- Cited by
- 410
- References
- 15
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.